Inogen (INGN) Cash from Operations Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | Inogen | 165.85 Mn | 71.44 Mn | 37.86 Mn | -1.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.99% |
| Dec 31, 2025 | 60.65% |
| Sep 30, 2025 | 30.62% |
| Jun 30, 2025 | -7.69% |
| Mar 31, 2025 | 2.47% |
| Dec 31, 2024 | -35.07% |
| Sep 30, 2024 | 63.06% |
| Jun 30, 2024 | -27.10% |
| Mar 31, 2024 | -54.12% |
| Dec 31, 2023 | -29.95% |
| Sep 30, 2023 | -31.32% |
| Jun 30, 2023 | -33.22% |
| Mar 31, 2023 | -139.10% |
| Dec 31, 2022 | -53.95% |
| Sep 30, 2022 | -38.37% |
| Jun 30, 2022 | -33.05% |
| Mar 31, 2022 | -114.88% |
| Dec 31, 2021 | -19.24% |
| Sep 30, 2021 | -30.22% |
| Jun 30, 2021 | -6.35% |
| Mar 31, 2021 | -38.41% |
| Dec 31, 2020 | 7.58% |
| Sep 30, 2020 | -27.05% |
| Jun 30, 2020 | -7.14% |
| Mar 31, 2020 | -65.55% |
| Dec 31, 2019 | 21.91% |
| Sep 30, 2019 | 17.26% |
| Jun 30, 2019 | 15.31% |
| Mar 31, 2019 | -33.55% |
| Dec 31, 2018 | -0.59% |
| Sep 30, 2018 | 6.65% |
| Jun 30, 2018 | 39.83% |
| Mar 31, 2018 | 26.40% |
| Dec 31, 2017 | 44.30% |
| Sep 30, 2017 | 75.62% |
| Jun 30, 2017 | 21.21% |
| Mar 31, 2017 | 128.52% |
| Dec 31, 2016 | 37.60% |
| Sep 30, 2016 | 25.32% |
| Jun 30, 2016 | 42.16% |
| Mar 31, 2016 | 21.05% |